Company Profile
Precision BioSciences Stock Price, News & Analysis
- Ticker:
- DTIL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.42 USD (-0.67%)
Close
Last updated: August 6, 2026
163M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, DTIL closed down 0.67% at $7.42. No new same-company headline was identified in the current news window.
Company overview
ARCUS Gene Editing Platform
Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material.
PBGENE-HBV
PBGENE-HBV is a wholly owned in vivo editing therapy in the Phase 1/2a ELIMINATE-B trial for chronic hepatitis B. It is designed to eliminate covalently closed circular DNA, the source of infectious viral replication, while inactivating integrated HBV DNA.
PBGENE-DMD
PBGENE-DMD uses two ARCUS nucleases delivered in one AAV to excise exons 45 through 55 of the dystrophin gene. The approach is intended to restore a near-full-length functional dystrophin protein in a large subset of patients with Duchenne muscular dystrophy and is entering the Phase 1/2 FUNCTION-DMD trial.
Partnered In Vivo Programs
iECURE is developing ECUR-506, an ARCUS-mediated gene-insertion therapy for neonatal-onset ornithine transcarbamylase deficiency. The OTC-HOPE study is evaluating whether targeted insertion can produce durable metabolic correction.
Partnered Cell Therapy
The allogeneic CAR-T candidate azer-cel is licensed to partners for development in lymphoma, progressive multiple sclerosis and other autoimmune diseases. These programs provide external validation and potential economics from an earlier ex vivo application of ARCUS technology.
Future catalysts
PBGENE-HBV clinical data at the EASL Congress on May 27–30, 2026, with further updates at hepatitis meetings during 2026.
Initial patient screening at new ELIMINATE-B sites in France and Romania expected in the second quarter of 2026.
First patient dosing and continued site expansion in the Phase 1/2 FUNCTION-DMD trial.
ECUR-506 clinical updates at ASGCT and SIMD in May 2026.
Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
Recent news
- 01
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Source: Precision BioSciences
- 02
- 03
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Source: Precision BioSciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Precision BioSciences (DTIL)?
Precision BioSciences (DTIL) most recently closed at 7.42 USD, a -0.67% move versus the previous session.
What is the market cap of Precision BioSciences (DTIL)?
Precision BioSciences currently has a market capitalization of 163M USD on BioPharmSignal.
What does Precision BioSciences do?
ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly owned in vivo editing...
On which exchange is DTIL stock listed?
Precision BioSciences (DTIL) is associated with NASDAQ, United States, Biopharma.
What is PBGENE-HBV?
PBGENE-HBV clinical data at the EASL Congress on May 27–30, 2026, with further updates at hepatitis meetings during 2026.
Which conditions is Precision BioSciences targeting with PBGENE-HBV?
Precision BioSciences is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does Precision BioSciences describe recent progress with PBGENE-HBV?
PBGENE-HBV clinical data at the EASL Congress on May 27–30, 2026, with further updates at hepatitis meetings during 2026.
What is ELIMINATE-B?
PBGENE-HBV PBGENE-HBV is a wholly owned in vivo editing therapy in the Phase 1/2a ELIMINATE-B trial for chronic hepatitis B.